ABVX:EPA
Abivax SA
€80.90
0.00%
(0.00) 1D
Okt 5, 5:35:21 PM GMT+2 · EUR
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa ABVX...
Mkt. cap
7.15B
Avg. na dami
156.16K
Dami
0.00
Mataas nang 52-wk
€139.00
Mababa nang 52-wk
€60.45
EPS
-€5.20
Mga natitirang share
87.53M
Bilang ng mga empleyado
98
Mkt. cap
7.15B
Avg. na dami
156.16K
Dami
0.00
Mataas nang 52-wk
€139.00
Mababa nang 52-wk
€60.45
EPS
-€5.20
Mga natitirang share
87.53M
Bilang ng mga empleyado
98
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Bloomberg.com
·
7 oras ang nakalipas
Stocks Edge Up to Near Record, Bonds Extend Slide
The Motley Fool
·
4 araw ang nakalipas
Will the Stock Market Crash? History Gives a 95% Reason to Stay Calm
MarketWatch
·
5 araw ang nakalipas
The 15 worst-performing S&P 500 stocks during a dismal September
Fox Business
·
4 araw ang nakalipas
October could be a huge month for the stock market. Here's why.
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Tungkol sa Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Mga Empleyado98
ItinatagDis 4, 2013
Headquarters-
Sektor-
Websiteabivax.com